Caladrius Biosciences

Developer of cell therapy based drugs for coronary microvascular dysfunction, diabetes, cancer and limbic ischemia

placeNew York City, New York, United States calendar_todayFounded 1980 groups53 employees language caladrius.com

Registered entities

Innovation

9 patent families (4 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace slowing. Cited 32 times.

YearFilings
20121
20151
20163
20171
20181
20202
20211
20221

Investor mix

3 investors on record.

Investor typeCountShare
Private equity133%
Other / undisclosed267%
Coming soon